UAE IVF Drugs and Food Supplements Market

In vitro fertilization (IVF) is a form of assisted reproductive technology in which a woman’s reproductive system is artificially stimulated to produce oocytes, which are extracted, fertilized in a laboratory, and then implanted in the uterus. This is a multistep process that needs to be carefully controlled with the use of medications due to the complex interplay of the various drugs used to replicate the different stages of the fertilization process by IVF healthcare team. IVF is a multistep process involving ovarian stimulation, ovulation induction, collection of oocytes, fertilization with sperm, and transfer of the fertilized oocytes to the uterus for implantation and maturation by following various stages. At each stage, there are different protocols for the use of these drugs, and the most appropriate pharmacologic regimen and therapeutic intervention are chosen after a thorough pre-treatment evaluation and an accurate diagnosis, controlled ovarian stimulation is achieved with the use of gonadotropin-releasing hormone (GnRH) analogues and inhibitors of natural steroid hormones, such as clomiphene citrate, recombinant follicle-stimulating hormone (FSH), and luteinizing hormone (LH) and also by providing food supplements to patients, such as Coenzyme Q10 (CoQ10) and DHEA are two supplements that are often used to help older women (over 35) and those with limited ovarian reserve. These are commonly used by women who are undergoing IVF to boost the number of eggs generated by their ovaries. Market Dynamics Key players and market players operating in the market are focusing on expanding and developing efficient IVF facilities which can be attributed to the growth of the UAE IVF drugs and food supplements market. For instance, on November 14, 2021, Mediclinic Middle East, which is a part of Mediclinic International and hospital group that operates seven hospitals in the UAE announced the 100% acquisition of Bourn Hall Fertility Centre, an IVF specialties center in the MENA region from TVM Capital Healthcare, following an initial acquisition of 30% of the shares in December 2018.The aim of this acquisition is to provide the highest level of quality care with exceptional outcomes through this acquisition to provide better services for IVF facilities. Key features of the study • This report provides an in-depth analysis of the UAE IVF drugs and food supplements, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the UAE IVF drugs and food supplements based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies • Key companies covered as a part of this study include Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The UAE IVF drugs and food supplements report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the UAE IVF drugs and food supplements market. Market Segmentation • By Product Type o Drugs  Clomiphene  Injectable Hormones (Human chorionic gonadotropin (hCG)  Follicle-stimulating hormone (FSH)  Human menopausal gonadotropin (hMG)  Gonadotropin-releasing hormone (GnRH)  GnRH agonist  GonGnRH antagonist o Food Supplements • By Distribution Channel o Hospitals Pharmacies o Retail Pharmacies o Online Pharmacies • Key Players o Shinelife o Adorefem o LG Chem o Adorshea o Biofield Pharma o Medibyte o Mestra Pharma o D Pharma o Abbott o Zydus o Takeda Pharmaceutical Company Limited o Merck KGaA o Ferring B.V.